Living dossier · Competitive landscape

TROP2 in Breast cancer

Primary identifiers: 8
Sponsors tracked: 8
Evidence types: 2 of 3
Last refreshed: 2026-07-28 · monthly

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

The most crowded target in the antibody-drug conjugate field, and the registry shows the contest has moved past whether it works. A striking share of the active studies are not efficacy trials at all — they are toxicity management, biomarker selection and imaging to predict who responds. That is the signature of a class where efficacy is settled and tolerability plus patient selection have become the live differentiators. The literature supplies the axis the trials do not: efflux-pump-mediated loss of payload, which is why next-generation constructs compete on linker and payload chemistry rather than on the antibody.

Programs and primary evidence

Sponsor	Asset	Phase	Mechanism	Primary source
GBG Forschungs GmbH	Sacituzumab govitecan (SASCIA)	3	TROP2-directed antibody-drug conjugate, post-neoadjuvant	NCT04595565 — Phase 3 post-neoadjuvant study in HER2-negative breast cancer with high relapse risk
SOLTI Breast Cancer Research Group	Sacituzumab govitecan	2	TROP2-directed ADC with prospective biomarker analysis	NCT06236269 — Prospective biomarker analysis in HR+/HER2- advanced or metastatic breast cancer
Fudan University	TROP2-PET patient selection	2	imaging-based prediction of anti-TROP2 ADC response	NCT07471776 — TROP2-PET and 18F-FDG PET to predict efficacy of anti-TROP2 ADC treatment in advanced breast cancer
Brown University	Dexamethasone mouthwash with datopotamab deruxtecan	2	toxicity management for a TROP-2 directed ADC	NCT06974604 — Prevention of datopotamab deruxtecan associated stomatitis (TROPION-DM)
Samsung Medical Center (Yeon Hee Park)	Sacituzumab govitecan with pegfilgrastim	2	neutropenia prophylaxis during TROP2 ADC therapy	NCT06616987 — Preventive effect of pegylated G-CSF on neutropenia in metastatic triple-negative breast cancer
Guangzhou Medical University	Sacituzumab govitecan + intrathecal chemotherapy	1/2	TROP2 ADC in a sanctuary site	NCT06462092 — Leptomeningeal metastases from HER2-negative breast cancer
OBI Pharma	OBI-992	—	TROP2-targeted ADC with an exatecan payload and cleavable hydrophilic linker	10.1158/1535-7163.MCT-24-0588 — Benchmarked against datopotamab deruxtecan and sacituzumab govitecan; retained activity in P-gp and BCRP overexpressing efflux models
Universiti Sains Malaysia	review	—	ADC mechanism, immune activation and resistance	10.1080/08830185.2025.2545364 — Resistance arises from heterogeneous antigen expression, altered ADC processing and upregulated drug-efflux pumps

Method and limits

Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
This page refreshes monthly (no net-new primary entity in 139 days). Mechanism classifications are our reading of the public record and may be revised.

Want the analysis behind this landscape?

The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.

Request the full dossier All landscapes